DoW Vision, Translational Research Award

The DoW Vision, Translational Research Award supports translational research that transforms a promising discovery into new drugs, devices, or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The award may be used to support preclinical studies, clinical research, or a pilot clinical trial, but not a full-scale clinical trial. Key elements of the award include the requirement for preliminary data, the option for a partnering principal investigator, and the need for the research to align with at least one of the FY26 VRP Focus Areas. • The maximum allowable funding for the entire period of performance is $1.6M for total costs. • The maximum period of performance is 3 years. • Preproposal submission is required, and application submission is by invitation only. • The award includes a partnering principal investigator option for two PIs, an initiating PI and a partnering PI. • Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel, and Post-Award Transition Plan.